Exemestane, a new steroidal aromatase inhibitor of clinical relevance - ScienceDirect
Strategies for Increasing the Effectiveness of Aromatase Inhibitors in | CMAR
JCI Insight - Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
Aromatase Inhibitors in Breast Cancer | NEJM
Breast Cancer Basics: Reducing Estrogen Receptor Stimulation (Without Drugs) – IOE Program by Dr. Brian Lawenda
Exemestane, a new steroidal aromatase inhibitor of clinical relevance - ScienceDirect
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review
Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane | Drug Metabolism & Disposition
Femara Aromatase Inhibitor ― Aromatase inhibitors (anastrozole, exemestane and letrozole)
Hypothesized mechanism of action of exemestane on MPM cells. The GPCR... | Download Scientific Diagram
Femara Aromatase Inhibitor ― Aromatase inhibitors (anastrozole, exemestane and letrozole)
Frontiers | Cognitive Effects of Aromatase and Possible Role in Memory Disorders | Endocrinology
Aromatase inhibitors drugs uses, aromatase inhibitors side effects
Exemestane, a new steroidal aromatase inhibitor of clinical relevance - ScienceDirect
Non steroidal aromatase inhibitors - Wikipedia
Anastrozole / Exemestane - Reproductive - Medbullets Step 1
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review
Acquired resistance to aromatase inhibitors: where we stand! in: Endocrine-Related Cancer Volume 25 Issue 5 (2018)
Metabolism and Toxicological Implications of Commonly Used Chemopreventive Drugs Against Breast Cancer/Carcinogenesis | Bentham Science
Hypothesized mechanism of action of exemestane on MPM cells. The GPCR... | Download Scientific Diagram
Figure 1 from Aromatase inhibitors in breast cancer: an update. | Semantic Scholar
Oncology
Exemestane, a new steroidal aromatase inhibitor of clinical relevance - ScienceDirect
Unravelling exemestane: From biology to clinical prospects - ScienceDirect
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
